Bayer’s Pipeline Gains Traction as Supreme Court Decision Looms Over Glyphosate Dispute
13.06.2026 - 14:25:16 | boerse-global.de
Bayer is hurtling toward a defining juncture where a breakthrough in kidney disease treatment is competing for investor attention with the outcome of a years-long legal battle. The Leverkusen-based group has reported positive Phase III data for its drug Kerendia in non-diabetic chronic kidney disease, while simultaneously bracing for a US Supreme Court ruling that could defuse or ignite a fresh wave of glyphosate litigation.
Kerendia clears a critical regulatory hurdle
The FIND-CKD trial met its primary endpoint, demonstrating that Kerendia significantly slows the decline of kidney function in patients without diabetes. Cardiovascular risks such as heart failure also dropped markedly compared with placebo. Bayer presented the findings at the European Renal Association congress and published them in the New England Journal of Medicine — a twin publication that the industry interprets as a strong signal of regulatory potential.
Kerendia is currently only approved for diabetic kidney disease. Expanding its label to the non-diabetic population would open up a vastly broader market: roughly 850 million people worldwide suffer from chronic kidney conditions, and more than half are non-diabetic. The new indication targets that larger pool directly.
Management reshuffle gathers pace
Amid the scientific progress, Bayer has been quietly restructuring its leadership. The consumer health division has appointed Samantha Avivi as global marketing chief, putting her in charge of brand strategy from the United States, the company’s largest market for over-the-counter medicines. For the first time, Bayer is also installing a dedicated US president for the consumer health unit.
Should investors sell immediately? Or is it worth buying Bayer?
The pharmaceutical side is seeing similar moves. Dr. Jost Reinhard, previously head of investor relations, will leave that post to take over radiology operations on August 1, 2026. He reports directly to pharma board member Stefan Oelrich, succeeding Nelson Ambrogio.
All eyes on Washington
The most consequential event for Bayer shareholders this quarter is not in a lab but in a courtroom. The US Supreme Court is expected to rule by the end of June on the Durnell case, a dispute that could determine whether Bayer can use federal law to shield itself from state-law glyphosate claims. A victory would essentially neuter around 80% of the remaining lawsuits.
Berenberg analyst Sebastian Bray puts the odds of a Bayer win at 60%, describing the situation as a coin toss. He has nudged his price target slightly higher, from €40.00 to €40.50, while maintaining a “Hold” rating, citing better margins in the pharma segment and favourable currency effects.
Even if the Supreme Court rules in Bayer’s favour, the company still needs to finalise a separate settlement agreement designed to head off future Roundup claims. The opt-out period for that deal, which could cost up to $7.25 billion, closed in Missouri at the start of June. CEO Bill Anderson has not yet disclosed how many plaintiffs chose to walk away; a court hearing for final approval is set for July.
Cash flow remains under strain
The legal overhang is exacting a visible toll on the balance sheet. In the first quarter, free cash flow plunged to minus €2.3 billion, which the group attributed largely to payouts for litigation settlements. Overall group revenue edged up to €13.4 billion on a currency-adjusted basis, and operating profit rose 9%, but the pharma division suffered a profit drop to €1.2 billion.
Bayer at a turning point? This analysis reveals what investors need to know now.
Stock treads water
The shares closed last Friday at €36.06, almost exactly on the 200-day moving average. Year-to-date, the stock is down about 5%, and it trades well below the 52-week high of nearly €50. The chart offers few short-term signals; the catalyst that truly matters is the Supreme Court’s verdict.
Bayer finds itself in a delicate balance: a win in Washington could remove a decade-long cloud, while a loss would inflate reserves for future settlements. Meanwhile, Kerendia’s progress gives the pipeline a tangible boost — but for now, the court calendar holds the upper hand in determining where the stock goes next.
Ad
Bayer Stock: New Analysis - 13 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
